Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BellaVie Children is a broad-spectrum synbiotic dietary supplement designed to support digestive health, immune function, and bone development in children. Developed by the Belgian laboratory BellaVie and marketed by Rameda, the product is formulated as a 'synbioceutical' combining eight probiotic/microbiotic strains (including *Bacillus coagulans*, *Bifidobacterium animalis lactis*, *Bifidobacterium infantis*, *Lactobacillus acidophilus*, *Lactobacillus helveticus*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus*, and *Saccharomyces boulardii*), prebiotic fiber (inulin), and nutraceuticals such as zinc bisglycinate and vitamin D3. It is intended to promote a favorable balance of the gut microbiota, support the immune system, and maintain good bone health in children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BellaVie Children.